SCHEDULE 13G/A 0001832106 XXXXXXXX LIVE 1 Common Stock, $0.001 par value per share 12/09/2024 0001861107 Ceribell, Inc. 15678C102 360 N. Pastoria Avenue Sunnyvale CA 94085 Rule 13d-1(c) ABG WTT-Ceribell Limited b E9 0.00 1691267.00 0.00 1691267.00 1691267.00 N 4.6 OO The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025. ABG V-Ceribell Limited b E9 0.00 1691267.00 0.00 1691267.00 1691267.00 N 4.6 CO ABG V-Ceribell Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025. Ally Bridge Group Global Life Science Capital Partners V, L.P. b E9 0.00 1691267.00 0.00 1691267.00 1691267.00 N 4.6 PN Ally Bridge Group Global Life Science Capital Partners V, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025. ABG Global Life Science Capital Partners V GP, L.P. b E9 0.00 1691267.00 0.00 1691267.00 1691267.00 N 4.6 PN ABG Global Life Science Capital Partners V GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025. ABG Global Life Science Capital Partners V GP Limited b E9 0.00 1691267.00 0.00 1691267.00 1691267.00 N 4.6 CO ABG Global Life Science Capital Partners V GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025. Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. b E9 0.00 1691267.00 0.00 1691267.00 1691267.00 N 4.6 PN Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025. ABG-WTT Global Life Science Capital Partners GP, L.P. b E9 0.00 1691267.00 0.00 1691267.00 1691267.00 N 4.6 PN ABG-WTT Global Life Science Capital Partners GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025. ABG-WTT Global Life Science Capital Partners GP Limited b E9 0.00 1691267.00 0.00 1691267.00 1691267.00 N 4.6 CO ABG-WTT Global Life Science Capital Partners GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025. ABG Management Ltd. b E9 0.00 1691267.00 0.00 1691267.00 1691267.00 N 4.6 CO ABG Management Ltd. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025 Ally Bridge Group (PE) LLC b DE 0.00 1691267.00 0.00 1691267.00 1691267.00 N 4.6 IA OO Ally Bridge Group (PE) LLC is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025. Fan Yu b O1 0.00 1691267.00 0.00 1691267.00 1691267.00 N 4.6 IN Fan Yu is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 37,095,690 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported on the Issuer's Form 10-Q filed on November 4, 2025. Ceribell, Inc. 360 N. Pastoria Avenue, Sunnyvale, California 94085 ABG WTT-Ceribell Limited ABG V-Ceribell Limited Ally Bridge Group Global Life Science Capital Partners V, L.P. ABG Global Life Science Capital Partners V GP, L.P. ABG Global Life Science Capital Partners V GP Limited Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. ABG-WTT Global Life Science Capital Partners GP, L.P. ABG-WTT Global Life Science Capital Partners GP Limited ABG Management Ltd. Ally Bridge Group (PE) LLC Fan Yu ABG WTT-Ceribell Limited c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG V-Ceribell Limited c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 Ally Bridge Group Global Life Science Capital Partners V, L.P. c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG Global Life Science Capital Partners V GP, L.P. c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG Global Life Science Capital Partners V GP Limited c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG-WTT Global Life Science Capital Partners GP, L.P. c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG-WTT Global Life Science Capital Partners GP Limited c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG Management Ltd. c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 Ally Bridge Group (PE) LLC 430 Park Avenue New York, New York 10022 United States of America Fan Yu c/o Maples Corporate Services Limited Ugland House, Grand Cayman Cayman Islands KY1-1104 ABG WTT-Ceribell Limited - Cayman Islands ABG V-Ceribell Limited - Cayman Islands Ally Bridge Group Global Life Science Capital Partners V, L.P. - Cayman Islands ABG Global Life Science Capital Partners V GP, L.P. - Cayman Islands ABG Global Life Science Capital Partners V GP Limited - Cayman Islands Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. - Cayman Islands ABG-WTT Global Life Science Capital Partners GP, L.P. - Cayman Islands ABG-WTT Global Life Science Capital Partners GP Limited - Cayman Islands ABG Management Ltd.- Cayman Islands Ally Bridge Group (PE) LLC - Delaware Fan Yu - Malta Y ABG WTT-Ceribell Limited: 1,691,267 ABG V-Ceribell Limited: 1,691,267 Ally Bridge Group Global Life Science Capital Partners V, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP Limited: 1,691,267 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.: 1,691,267 ABG-WTT Global Life Science Capital Partners GP, L.P.: 1,691,267 ABG-WTT Global Life Science Capital Partners GP Limited: 1,691,267 ABG Management Ltd.: 1,691,267 Ally Bridge Group (PE) LLC: 1,691,267 Fan Yu: 1,691,267 ABG WTT-Ceribell Limited: 4.6% ABG V-Ceribell Limited: 4.6% Ally Bridge Group Global Life Science Capital Partners V, L.P. : 4.6% ABG Global Life Science Capital Partners V GP, L.P. : 4.6% ABG Global Life Science Capital Partners V GP Limited: 4.6% Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 4.6% ABG-WTT Global Life Science Capital Partners GP, L.P.: 4.6% ABG-WTT Global Life Science Capital Partners GP Limited: 4.6% ABG Management Ltd.: 4.6% Ally Bridge Group (PE) LLC: 4.6% Fan Yu: 4.6% ABG WTT-Ceribell Limited: 0 ABG V-Ceribell Limited: 0 Ally Bridge Group Global Life Science Capital Partners V, L.P. : 0 ABG Global Life Science Capital Partners V GP, L.P. : 0 ABG Global Life Science Capital Partners V GP Limited: 0 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 0 ABG-WTT Global Life Science Capital Partners GP, L.P.: 0 ABG-WTT Global Life Science Capital Partners GP Limited: 0 ABG Management Ltd.: 0 Ally Bridge Group (PE) LLC: 0 Fan Yu: 0 ABG WTT-Ceribell Limited: 1,691,267 ABG V-Ceribell Limited: 1,691,267 Ally Bridge Group Global Life Science Capital Partners V, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP Limited: 1,691,267 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 1,691,267 ABG-WTT Global Life Science Capital Partners GP, L.P.: 1,691,267 ABG-WTT Global Life Science Capital Partners GP Limited: 1,691,267 ABG Management Ltd.: 1,691,267 Ally Bridge Group (PE) LLC: 1,691,267 Fan Yu: 1,691,267 ABG WTT-Ceribell Limited: 0 ABG V-Ceribell Limited: 0 Ally Bridge Group Global Life Science Capital Partners V, L.P. : 0 ABG Global Life Science Capital Partners V GP, L.P. : 0 ABG Global Life Science Capital Partners V GP Limited: 0 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 0 ABG-WTT Global Life Science Capital Partners GP, L.P.: 0 ABG-WTT Global Life Science Capital Partners GP Limited: 0 ABG Management Ltd.: 0 Ally Bridge Group (PE) LLC: 0 Fan Yu: 0 ABG WTT-Ceribell Limited: 1,691,267 ABG V-Ceribell Limited: 1,691,267 Ally Bridge Group Global Life Science Capital Partners V, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP, L.P.: 1,691,267 ABG Global Life Science Capital Partners V GP Limited: 1,691,267 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. : 1,691,267 ABG-WTT Global Life Science Capital Partners GP, L.P.: 1,691,267 ABG-WTT Global Life Science Capital Partners GP Limited: 1,691,267 ABG Management Ltd.: 1,691,267 Ally Bridge Group (PE) LLC: 1,691,267 Fan Yu: 1,691,267 N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. ABG WTT-Ceribell Limited By: /s/ Kevin Reilly 12/11/2025 ABG V-Ceribell Limited By: /s/ Kevin Reilly 12/11/2025 Ally Bridge Group Global Life Science Capital Partners V, L.P. By: ABG Global Life Science Capital Partners V GP, L.P., its general partner, By: ABG Global Life Science Capital Partners V GP Limited, its general p 12/11/2025 ABG Global Life Science Capital Partners V GP, L.P. By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Fan Yu 12/11/2025 ABG Global Life Science Capital Partners V GP Limited By: /s/ Fan Yu 12/11/2025 Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner, By: ABG-WTT Global Life Science Capital Partners GP Limited, its gener 12/11/2025 ABG-WTT Global Life Science Capital Partners GP, L.P. By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner, By: /s/ Fan Yu 12/11/2025 ABG-WTT Global Life Science Capital Partners GP Limited By: /s/ Fan Yu 12/11/2025 ABG Management Ltd. By: /s/ Fan Yu 12/11/2025 Ally Bridge Group (PE) LLC By: ABG Management Ltd., its managing member, By: /s/ Fan Yu 12/11/2025 Fan Yu By: /s/ Fan Yu 12/11/2025 The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent. Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).